

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E. Afar et al. Examiner: G. Nickol
Serial No.: 09/323,597 Group Art Unit: 1642
Filed: June 1, 1999 Docket: G&C 129.8-US-U1
Title: NOVEL TUMOR ANTIGEN USEFUL IN DIAGNOSIS AND THERAPY OF
PROSTATE AND COLON CANCER

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2001.

By: W. J. Wood

Name: William J. Wood

RECEIVED

MAR 08 2001

TECH CENTER 1600/290

RESPONSE TO OFFICE COMMUNICATION DATED 12/12/00

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is a corrected Sequence Listing in paper and computer-readable format in response to the Examiner's request for same in a Communication dated December 12, 2000 (paper # 17). Please amend the above-mentioned Application by entering this substitute paper copy of the Sequence Listing into the specification. The content of the paper and computer-readable copies of this corrected Sequence Listing are the same. The corrected Sequence Listing includes no new matter.

Respectfully submitted,

Daniel E. Afar et al.

By their attorneys,

GATES & COOPER LLP

6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797

By: W. J. Wood

Name: William J. Wood

Reg. No.: 42,236

Date: February 12, 2001

WJW/sjm

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY